Genetics of the Acute Response to Alcohol in Social Drinkers
Alcoholism, Genetics
About this trial
This is an interventional treatment trial for Alcoholism focused on measuring Alcohol Clamp, Pharmacogenetics, Family History of Alcoholism, Pharmacodynamics, Healthy Volunteer, HV
Eligibility Criteria
- INCLUSION CRITERIA:
Male and female participants between 21-30 years of age.
Good health as determined by medical history, physical exam, EKG and lab tests.
EXCLUSION CRITERIA:
Current or prior history of any disease, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders.
Positive hepatitis or HIV test at screening.
Current (i.e., in the past year) diagnosis of Axis-I psychiatric illness.
Current or lifetime diagnosis of alcohol or substance dependence.
Currently (i.e., in the past year) seeking treatment for alcohol-related problems.
Non-drinkers (alcohol-na(SqrRoot) ve individuals or current abstainers), or individuals who have never consumed more than 4 drinks on at least one occasion.
Current or prior history of alcohol-induced flushing reaction, including rapid reddening of the face, rapid heart rate and breathing, and nausea after 1 or 2 drinks.
Regular tobacco users will be excluded from the study in order to avoid nicotine withdrawal symptoms. Occasional use of tobacco products (up to 20 cigarettes/week, Fagerstrom Test for Nicotine Dependence Score less than 4) is acceptable.
Positive result on urine drug screen or breathalyzer test at screening
No regular use of medications for the last 3 months. Use of prescription or OTC medications known to interact with alcohol within 2 weeks of the study. These include, but may not be limited to: isosorbide, nitroglycerine, benzodiazepines, warfarin, anti-depressants such as amitriptyline, clomipramine and nefazodone, anti-diabetes medications such as glyburide, metformin and tolbutamide, H2-antagonists for heartburn such as cimetidine and ranitidine, muscle relaxants, anti-epileptics including phenytoin and phenobarbital codeine, and narcotics including darvocet, percocet and hydrocodone. Drugs known to inhibit or induce enzymes that metabolize alcohol should not be used for 4 weeks prior to the study. These include chlorzoxazone, isoniazid, metronidazole and disulfiram. Cough-and-cold preparations which contain anti-histamines, pain medicines and anti-inflammatories such as aspirin, ibuprofen, acetaminophen, celecoxib and naproxen, should be withheld for at least 72 hours prior to each study session.
Females must not be pregnant or breast-feeding. Female participants will undergo a urine beta-hCG test to ensure they are not pregnant during screening and study visits.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike